Navigation Links
PPD Expands Global Central Lab Services into China
Date:1/23/2008

WILMINGTON, N.C., Jan. 23 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced that it has expanded its global central lab services into China through an exclusive agreement with Peking Union Lawke Biomedical Development Limited (PUL). The agreement allows PPD to begin immediately providing biopharmaceutical clients with its full range of highly customized central lab services in China.

"Chinese law makes it extremely difficult to export lab samples to other countries for testing," said Agostino L. Fede, Ph.D., senior vice president of PPD and head of PPD's global central labs. "Our agreement with PUL expands our global central lab capabilities in a high growth clinical research market. It also saves our clients time and money by providing lab results more quickly without incurring expenses for exporting shipments."

Under the terms of the agreement, PPD invested in laboratory equipment located at Peking Union Medical College in the Beijing Zhong Guan Cun Life Sciences Park, the largest life sciences park in China. The equipment is identical to platforms located at PPD's global central labs in Brussels, Belgium, and Highland Heights, Ky., and assays performed have been extensively cross validated and precisely calibrated to match instruments at these labs. With these and other ongoing quality assurance measures, PUL and PPD deliver laboratory data that are directly combinable. In addition, PUL is interfaced real-time to ConneXion, PPD's proprietary computer system, to assure consistent management and reporting.

Jian Ho, M.D., Ph.D., medical director at PUL, will oversee the lab while PPD will lead project management and investigator services and work with clients on study setup. As part of the agreement, PUL will conduct chemistry, hematology, urinalysis and hemoglobin A1c tests to support PPD's clinical trials business in China. PUL also offers an extensive range of esoteric tests. In return, PUL will have rights to use the equipment to conduct central lab testing for Chinese clients running clinical trials in China.

"PUL provides reference testing services to hospitals, clinics and is the largest reference lab in Beijing," said Dr. Ho. "We are pleased to use our experience across numerous lab platforms to support PPD's global central labs."

The PUL global central lab participates in the College of American Pathologists (CAP) external proficiency testing program and has applied for CAP accreditation. PUL is performing National Glycohemoglobin Standards Program testing in anticipation of accreditation.

This year marks PPD's 20th anniversary providing global central lab services.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the expansion of PPD global central lab services, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: risks associated with and dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; continued success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; competition within the outsourcing industry; the ability to attract and retain key personnel; risks associated with the development and commercialization of drugs, including earnings dilution and obtaining regulatory approval; risks associated with acquisitions and investments, such as impairments; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts

Media:

Sue Ann Pentecost

+919 456 5890

sueann.pentecost@rtp.ppdi.com

Analysts/Investors:

Craig Eastwood

+910 558 7585

craig.eastwood@wilm.ppdi.com


'/>"/>
SOURCE PPD, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ATS Medical Expands Open Pivot Heart Valve Offerings
2. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
3. BioLife Solutions Expands Scientific Advisory Board
4. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
5. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
6. Pharsight Expands Strategic Consulting Services Team
7. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
8. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
9. AQUISS Expands Into Significant New Territory
10. NanoBio Expands Drug Development Team for Its Anti-Infective Products
11. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... 16, 2017 , ... Tunnell Consulting announced today that four of ... Annual Meeting and Expo , to be held October 29 through November 1 in ... innovation to advance patient therapies.” , The ISPE Annual Meeting and Expo will feature ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... microbe delivery system, announced it has secured $2M in funding from an impressive ... Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar is broadening ...
(Date:8/15/2017)... spending the past two years building a state-of-the-art technology which consolidates ... this platform to healthcare stakeholders (hospitals, foundations, biopharma companies etc.) who ... vis a vis their members, under their own brand. Three recent ... ... ...
(Date:8/15/2017)... ... August 15, 2017 , ... Any expert in stem cell research or stem ... more than half a century. Despite their essential roles in human health and ... that molecular tags developed for this purpose also tag other, more abundant, non-stem tissue ...
Breaking Biology Technology:
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 /PRNewswire/ ... leader in dairy research, today announced a new collaboration ... reduce the chances that the global milk supply is ... dairy project, Cornell University has become the newest academic ... Supply Chain, a food safety initiative that includes IBM ...
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
Breaking Biology News(10 mins):